In Brief: Genzyme Seprafilm
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Seprafilm: Follow-up at 8-12 weeks post-surgery shows that 51% of abdominal surgery patients treated with the bioresorbable membrane do not develop adhesions, according to results of a study presented Oct. 24 at the American College of Surgeons meeting in New Orleans. The success rate compares to a 6% rate for control patients who did not receive the membrane in the 11-center, 183-subject, prospective, randomized, blinded study. Cambridge, Massachusetts-based Genzyme says it plans to submit the data, along with data from a study of gynecologic surgery, in a PMA for Seprafilm...
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.